Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$9.11
▲ $0.16 (+1.8%)
Market data updated: 09/19 02:58 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$2.04B
Day Range
$8.81 - $9.13
52-Week Range
$7.21 - $20.46
Beta
—
Next Earnings
03.11.2026
Support
$8.16
Resistance
$10.35
ADMA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-43.6% (1Y)
Strengths: 14/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: $2.96 vs. price $9.11 (-67.5%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
37
Quality
63
Value
38
Momentum
32
Risk
62
Sentiment
38
Fundamental
83
Institutional
60
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of ADMA Biologics Inc has focused on its financial performance and stock volatility, particularly around its Q2 2026 earnings report. The company saw mixed results, with **ASCENIV** showing a 24% revenue surge but **BIVIGAM** contributing to missed revenue estimates, leading to a stock decline. Analysts debated its investment potential, downgrading the stock to *Hold* due to slower growth and lowered FY26 guidance, while others suggested lingering upside from ASCENIV. Broker opinions and earnings comparisons dominated discussions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about ADMA Biologics Inc. News trend score: 38. Reason: 6 of the last 20 articles are negative, versus 4 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
42
Psychology
45
Fundamentals
83
Technical
32
Valuation
38
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+10%
Market Narrative
49
Fundamental Reality
42
Narrative Gap
+7
🧠 StockIQ Psychologist
ADMA’s dominant herding behavior reflects a market where participants align with peers rather than fundamentals or momentum. The narrative-reality gap (14 points) hints at a disconnect between investor perceptions and objective metrics, while overconfidence in valuation (+222% DCF premium) may blind traders to relative underperformance. Key uncertainty remains: whether herding persists or shifts as valuation strains under negative momentum. The absence of panic or FOMO signals suggests a cautious, not desperate, crowd.
Updated: 09/08/2026, 10:49 PM
What could change this?
👥 What the crowd believes
"ASCENIV surges 24% as gross margins improve (GuruFocus.com)"
"Revenues miss on Bivigam weakness (Zacks)"
"Shares slide as Q2 results miss estimates (ChartMill)"
"FY26 guidance drops and growth slows (SeekingAlpha)"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jesse Livermore — 26/100
🗣️ Why do they disagree?
The stark divide in verdicts for ADMA reflects deep philosophical and methodological differences among these investors. Walter Bagehot’s near-perfect score highlights his focus on liquidity and resilience during crises, suggesting the stock’s stability in a credit squeeze—something few others prioritized. Meanwhile, growth-oriented investors like Edgar Lawrence Smith and Philip Fisher see potential as a long-term hold, though Fisher’s lower score indicates it lacks the exceptional quality he sought. On the other end, Benjamin Graham and Jack Schwager’s low scores reveal their skepticism: Graham’s strict valuation tests and Schwager’s disciplined, pattern-driven approach both flag the stock as lacking clear edge or margin of safety. Even mixed signals from Marks, Lynch, and Veblen underscore a middle-ground uncertainty—growth may exist, but either expectations are already priced in or profitability isn’t yet proven. The contrast between Bagehot’s liquidity focus and Graham’s valuation rigor perfectly illustrates why some methodologies see opportunity where others see risk.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 84
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 77
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 72
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 68
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 66
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 64
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 62
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 56
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 54
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 53
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 51
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 47
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 42
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 39
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 26
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
57.4%
Operating Margin
37.5%
Net Margin
28.8%
EBITDA Margin
39.1%
ROE
30.8%
ROA
23.5%
ROIC
—
EPS
$0.62
Cash
$87.63M
Total Debt
$72.14M
Current Ratio
6.71
Debt/Equity
0.15
How is Fair Value calculated? →
Current Price
$9.11
Estimated Fair Value (DCF)
$2.96
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-67.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $34.78M | $31.90M |
| 2 | 19.4% | $41.51M | $34.94M |
| 3 | 13.8% | $47.22M | $36.46M |
| 4 | 8.1% | $51.06M | $36.17M |
| 5 | 2.5% | $52.34M | $34.01M |
Base FCF (last actual year)
$27.82M
Terminal Value
$825.29M
Present Value of Terminal Value
$536.38M
Enterprise Value
$709.88M
Net Debt
$-15.49M
Equity Value
$725.37M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.95
Tangible Book Value per Share (Tangible NAV)
$1.93
Sentiment based on basic keywords (not AI) — 4 positive, 10 neutral, 6 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 11.9.2026
Yahoo · 10.9.2026
Zacks · 10.9.2026
Yahoo · 8.9.2026
Zacks · 8.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
SeekingAlpha · 2.9.2026
SeekingAlpha · 16.8.2026
SeekingAlpha · 12.8.2026
Zacks · 6.8.2026
GuruFocus.com · 6.8.2026
ChartMill · 5.8.2026
MarketBeat · 5.8.2026
Associated Press · 5.8.2026
GlobeNewswire · 5.8.2026
SeekingAlpha · 5.8.2026
Benzinga · 5.8.2026
Benzinga · 5.8.2026
ADMA Biologics Inc (ADMA) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ADMA currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ADMA's estimated fair value is $2.96, which is 67.5% below the current price of $9.11. This is one valuation model among several signals in the fair-value category, not a price target.
ADMA's technical score is 32/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Return on equity (ROE): 30.8% — strong; Debt/equity: 0.15.
Based on the real signals StockIQ computed: Estimated fair value: $2.96 vs. price $9.11 (-67.5%); Earnings per share (EPS) growth: -25.9%; Free cash flow growth: -74.8%.
StockIQ has no recorded dividend payment history for ADMA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 6 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Kestenberg-Messina Kaitlin M. | Tax Withholding in Shares | 24.7.2026 | 3,177 | -3,177 | $8.37 |
| Kestenberg-Messina Kaitlin M. | Tax Withholding in Shares | 24.7.2026 | 443,061 | -3,177 | $8.37 |
| Kohler Terry | Grant/Award from Employer | 16.7.2026 | 85,130 | +85,130 | — |
| Kohler Terry | Grant/Award from Employer | 16.7.2026 | 136,363 | +136,363 | — |
| Kohler Terry | Grant/Award from Employer | 16.7.2026 | 143,149 | +85,130 | — |
| Kohler Terry | Grant/Award from Employer | 16.7.2026 | 136,363 | +136,363 | — |
| Grossman Jerrold B | Open Market Purchase | 27.5.2026 | 6,400 | +6,400 | $7.91 |
| Grossman Jerrold B | Open Market Purchase | 27.5.2026 | 520,284 | +6,400 | $7.91 |
| Grossman Jerrold B | Open Market Purchase | 12.5.2026 | 12,500 | +12,500 | $8.01 |
| Grossman Jerrold B | Open Market Purchase | 12.5.2026 | 513,884 | +12,500 | $8.01 |
| Grossman Jerrold B | Open Market Purchase | 11.5.2026 | 12,500 | +12,500 | $8.01 |
| Grossman Jerrold B | Open Market Purchase | 11.5.2026 | 501,384 | +12,500 | $8.01 |
| Kestenberg-Messina Kaitlin M. | Tax Withholding in Shares | 1.4.2026 | 20,362 | -20,362 | $9.11 |
| Kestenberg-Messina Kaitlin M. | Tax Withholding in Shares | 1.4.2026 | 446,238 | -20,362 | $9.11 |
| Guiheen Lawrence P. | Gift | 17.3.2026 | 30,000 | -30,000 | — |
| Guiheen Lawrence P. | Gift | 17.3.2026 | 30,000 | +30,000 | — |
| Guiheen Lawrence P. | Gift | 17.3.2026 | 105,520 | -30,000 | — |
| Guiheen Lawrence P. | Gift | 17.3.2026 | 30,000 | +30,000 | — |
| Grossman Adam S | Exercise of Derivative Securities | 16.3.2026 | 15,000 | -15,000 | — |
| Grossman Adam S | Exercise of Derivative Securities | 16.3.2026 | 15,000 | +15,000 | $5.40 |
| Grossman Adam S | Open Market Sale | 16.3.2026 | 6,000 | -6,000 | $15.16 |
| Grossman Adam S | Open Market Sale | 16.3.2026 | 15,000 | -15,000 | $15.16 |
| Grossman Adam S | Exercise of Derivative Securities | 16.3.2026 | 2,133,777 | +15,000 | $5.40 |
| Grossman Adam S | Open Market Sale | 16.3.2026 | 2,118,777 | -15,000 | $15.16 |
| Grossman Adam S | Open Market Sale | 16.3.2026 | 2,112,777 | -6,000 | $15.16 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
23,870,475 shares short as of 2026-08-31 · vs. 21,918,195 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
58.6% of trading volume this week was short selling, vs. 56.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology